MX2019005700A - Metodos para tratar la osteocondromatosis multiple (mo). - Google Patents

Metodos para tratar la osteocondromatosis multiple (mo).

Info

Publication number
MX2019005700A
MX2019005700A MX2019005700A MX2019005700A MX2019005700A MX 2019005700 A MX2019005700 A MX 2019005700A MX 2019005700 A MX2019005700 A MX 2019005700A MX 2019005700 A MX2019005700 A MX 2019005700A MX 2019005700 A MX2019005700 A MX 2019005700A
Authority
MX
Mexico
Prior art keywords
osteochondroma
methods
subject
treating multiple
growth
Prior art date
Application number
MX2019005700A
Other languages
English (en)
Inventor
Desjardins Clarissa
Roy Grogan Donna
Lemire Isabelle
Harvey Michael
Original Assignee
Clementia Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clementia Pharmaceuticals Inc filed Critical Clementia Pharmaceuticals Inc
Publication of MX2019005700A publication Critical patent/MX2019005700A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención presenta métodos para inhibir la formación, reducir el tamaño y ralentizar el crecimiento de un osteocondroma en un sujeto con osteocondromatosis múltiple (MO) mediante la administración al sujeto de palovarotene (también denominado R667), o una sal aceptable desde el punto de vista farmacéutico de este. Los métodos descritos en la presente también pueden aliviar complicaciones asociadas con la formación y crecimiento de osteocondromas en un sujeto con MO.
MX2019005700A 2016-11-16 2017-11-16 Metodos para tratar la osteocondromatosis multiple (mo). MX2019005700A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662423019P 2016-11-16 2016-11-16
PCT/CA2017/051368 WO2018090137A1 (en) 2016-11-16 2017-11-16 Methods for treating multiple osteochondroma (mo)

Publications (1)

Publication Number Publication Date
MX2019005700A true MX2019005700A (es) 2020-01-21

Family

ID=62144988

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005700A MX2019005700A (es) 2016-11-16 2017-11-16 Metodos para tratar la osteocondromatosis multiple (mo).

Country Status (14)

Country Link
US (1) US10980778B2 (es)
EP (1) EP3541380B1 (es)
JP (1) JP7018957B2 (es)
KR (1) KR20190100187A (es)
CN (1) CN110381939B (es)
AU (1) AU2017359673B2 (es)
BR (1) BR112019009929A2 (es)
CA (1) CA3043807A1 (es)
EA (1) EA039050B1 (es)
ES (1) ES2907696T3 (es)
IL (1) IL266605A (es)
MX (1) MX2019005700A (es)
SG (1) SG10202105186XA (es)
WO (1) WO2018090137A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230218576A1 (en) * 2020-06-11 2023-07-13 Yang Sheng Tang Company, Ltd. Use of palovarotene in treatment against hbv virus
CN118460478A (zh) * 2024-07-15 2024-08-09 山东大学 一株多发性骨软骨瘤诱导多能干细胞系及其应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824685A (en) 1995-02-01 1998-10-20 The Johns Hopkins University School Of Medicine Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
US5624957A (en) 1995-06-06 1997-04-29 Bristol-Myers Squibb Company Rary-specific retinobenzoic acid derivatives
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
US7514074B2 (en) 1997-07-14 2009-04-07 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
US6204288B1 (en) 1999-03-08 2001-03-20 The University Of Mississippi 1,2-dithiolane derivatives
US20030114482A1 (en) 1999-12-15 2003-06-19 Maurizio Pacifici Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
US6313168B1 (en) 1999-12-15 2001-11-06 Allergan Sales, Inc. Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
JP2003526677A (ja) 2000-03-14 2003-09-09 ザ・ユニバーシテイ・オブ・ウエスタン・オンタリオ 骨形成に影響を与える組成物および方法
AU2001289913B2 (en) 2000-10-02 2006-08-17 F. Hoffmann-La Roche Ag Retinoids for the treatment of emphysema
EP1430024A1 (en) 2001-09-18 2004-06-23 F. Hoffmann-La Roche Ag Alkyl urea retinoid agonists i
BR0212607A (pt) 2001-09-18 2004-08-17 Hoffmann La Roche Agonistas retinóides ii de uréia substituìda
AUPR892501A0 (en) 2001-11-16 2001-12-13 Peter Maccallum Cancer Institute, The Method of enhancing self renewal of stem cells and uses thereof
US20050101581A1 (en) 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
JP2005206544A (ja) 2004-01-23 2005-08-04 Yasuyoshi Uchida 筋肉再生剤
AU2005240078A1 (en) 2004-04-30 2005-11-17 Allergan, Inc. Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing
WO2005115304A2 (en) 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating fibrodysplasia
KR20070121758A (ko) 2005-03-17 2007-12-27 엘란 파마 인터내셔널 리미티드 나노입자형 면역 억제 화합물의 주사가능한 조성물
US7345931B2 (en) 2005-08-01 2008-03-18 Infineon Technologies Ag Maintaining internal voltages of an integrated circuit in response to a clocked standby mode
US20090281184A1 (en) 2005-09-27 2009-11-12 Sapporo Medical University Pharmaceutical for prevention and treatment of ophthalmic disease induced by in-crease in vasopermeability
BRPI0709886A2 (pt) * 2006-03-31 2011-07-26 Hoffmann La Roche processo para a preparaÇço de compostos retinàides
EP2026778B1 (en) 2006-05-16 2018-11-14 Io Therapeutics, LLC Rar antagonist or inverse agonist for use in the treatment of chemotherapy and/or radiation therapy side effects
US8614103B2 (en) 2006-10-27 2013-12-24 Lpath, Inc. Compositions and methods for treating sphingosine-1-phosphate (S1P) related ocular diseases and conditions
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
WO2009114180A1 (en) 2008-03-13 2009-09-17 The General Hospital Corporation Inhibitors of the bmp signaling pathway
EP2379174A4 (en) 2008-12-18 2012-11-14 Astrazeneca Ab PHARMACEUTICAL PRODUCT USING A P38 KINASE INHIBITOR AND A SECOND ACTIVE SUBSTANCE
WO2010088735A1 (en) 2009-02-05 2010-08-12 Regenertech Pty Ltd Method of producing progenitor cells from differentiated cells
US20120277156A1 (en) 2009-07-21 2012-11-01 University Of Washington Trhough It's Center For Commercialization Inhibition of pathological bone formation
BR112013004685B1 (pt) 2010-09-01 2021-09-21 Thomas Jefferson University Uso de um agonista de receptor gama de ácido retinóico (rar?) para reparação e regeneração muscular
CA2812952A1 (en) 2010-09-27 2012-04-12 Microdose Therapeutx, Inc. Methods and compositions for disease treatment using inhalation
US10485780B2 (en) * 2011-03-14 2019-11-26 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the treatment of proliferative disorders
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
EP2726084A1 (en) 2011-07-01 2014-05-07 The United States of America, as represented by The Secretary, Department of Health and Human Services Method of treating pathologic heterotopic ossification
CN105188753B (zh) 2012-11-08 2018-12-18 国立大学法人山口大学 角结膜病症的治疗剂
US20160115167A1 (en) 2013-03-04 2016-04-28 The Brigham And Women's Hospital, Inc. Bmp inhibitors and methods of use thereof
JP6542192B2 (ja) 2013-03-14 2019-07-10 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． Ｂｍｐ阻害剤およびその使用方法
KR102303316B1 (ko) 2013-05-22 2021-09-23 고쿠리츠다이가쿠호우진 야마구치 다이가쿠 망막 맥락막 장해의 억제제
EP3201187A4 (en) 2014-10-01 2018-04-11 The Brigham and Women's Hospital, Inc. Compositions and methods for inhibiting bmp
WO2017070194A1 (en) 2015-10-19 2017-04-27 The Children's Medical Center Corporation Method to inhibit endothelial-to-mesenchymal transition
WO2017112431A1 (en) 2015-12-24 2017-06-29 The Regents Of The University Of Michigan Method of treating heterotopic ossification
ES2963348T3 (es) * 2016-06-08 2024-03-26 Clementia Pharmaceuticals Inc Métodos para tratar la osificación heterotópica

Also Published As

Publication number Publication date
BR112019009929A2 (pt) 2019-08-20
ES2907696T3 (es) 2022-04-26
EA039050B1 (ru) 2021-11-26
US10980778B2 (en) 2021-04-20
EP3541380A1 (en) 2019-09-25
CN110381939B (zh) 2022-12-02
JP2019534336A (ja) 2019-11-28
AU2017359673A1 (en) 2019-06-27
AU2017359673B2 (en) 2021-10-21
SG10202105186XA (en) 2021-06-29
US20190275005A1 (en) 2019-09-12
KR20190100187A (ko) 2019-08-28
EP3541380B1 (en) 2021-12-15
EP3541380A4 (en) 2020-12-09
JP7018957B2 (ja) 2022-02-14
IL266605A (en) 2019-07-31
CN110381939A (zh) 2019-10-25
CA3043807A1 (en) 2018-05-24
WO2018090137A1 (en) 2018-05-24
EA201991208A1 (ru) 2019-10-31

Similar Documents

Publication Publication Date Title
JOP20200011A1 (ar) مركبات وتركيبات لمعالجة حالات مرضية مرتبطة بنشاط nlrp
MX2018003472A (es) Moduladores de la expresion de kras.
SG10201901010PA (en) Combination therapy for treating a paramyxovirus
MX2017008720A (es) Derivados y metodos para tratamiento de las infecciones por hepatitis b.
EP4282479A3 (en) Use of pridopidine to treat depression or anxiety
TW201613872A (en) IRAK4 inhibiting agents
MX2022007221A (es) Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos.
WO2019040106A3 (en) COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES
EA201891340A1 (ru) Лечение рака с использованием 2-дезокси-2-фтор-l-фукозы в комбинации с ингибитором контрольных точек
MX338610B (es) Composiciones farmaceuticas que comprenden sulbactam e inhibidor de beta-lactamasa.
PH12015501588A1 (en) Compounds and methods for treating bacterial infections
MX2015016319A (es) Terapia de combinacion que comprende oxazolidinona-quinolonas para uso en el tratamiento de infecciones bacterianas.
PH12016501751A1 (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
PH12017501741A1 (en) Histamine-producing bacterial strains and their use in cancer
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
PH12016502322A1 (en) Compounds and methods for preventing or treating malaria
NZ730092A (en) Use of cysteamine in treating infections caused by yeasts/moulds
SG10201811078XA (en) Method Of Treatment Of Hypoxia Inducible Factor (HIF)-Related Conditions
ZA202200511B (en) Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of tuberculosis
MX2019002901A (es) Tratamiento de esclerosis multiple con chs-131.
MX2019000677A (es) Células miméticas de células b.
MX2019005700A (es) Metodos para tratar la osteocondromatosis multiple (mo).
WO2019040105A3 (en) COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES
WO2015142865A3 (en) Metakaryocidal treatments
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms